{"id":"NCT00660673","sponsor":"AbbVie","briefTitle":"Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease","officialTitle":"Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11-13","primaryCompletion":"2021-11-30","completion":"2021-11-30","firstPosted":"2008-04-17","resultsPosted":"2022-12-02","lastUpdate":"2022-12-02"},"enrollment":262,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Levodopa-Carbidopa Intestinal Gel (LCIG)","otherNames":["Carbidopa-Levodopa Enteral Suspension (CLES)","Duopa®","Duodopa®"]},{"type":"DEVICE","name":"CADD-Legacy® 1400 ambulatory infusion pump","otherNames":[]},{"type":"DEVICE","name":"Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)","otherNames":[]}],"arms":[{"label":"Levodopa-Carbidopa Intestinal Gel","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment (Study S187.3.003 \\[NCT00360568\\] or Study S187.3.004 \\[NCT00335153\\]).","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events","timeFrame":"From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).","effectByArm":[{"arm":"Levodopa-Carbidopa Intestinal Gel","deltaMin":253,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":null,"healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":61,"countries":["United States","Australia","Canada","Czechia","Israel","New Zealand","Poland","Portugal","Russia","Thailand","United Kingdom"]},"refs":{"pmids":["29570853"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":159,"n":262},"commonTop":["VITAMIN B6 DECREASED","BLOOD HOMOCYSTEINE INCREASED","POSTOPERATIVE WOUND INFECTION","FALL","URINARY TRACT INFECTION"]}}